PFE 輝瑞

26.05
-0.14
(-0.52%)

輝瑞 PFE

單位：USD
26.05
-0.14
(-0.52%)
製藥
成交股數
21.9萬
本益比
18.48
市值 1484.28億
報價時間 | -
單位：美金千元
科目 2024/Q4 2024/Q3 2024/Q2 2024/Q1 2023/Q4 2023/Q3 2023/Q2 2023/Q1 2022/Q4 2022/Q3 2022/Q2 2022/Q1 2021/Q4 2021/Q3 2021/Q2 2021/Q1 2020/Q4 2020/Q3 2020/Q2 2020/Q1
營業現金流
6,721,000 6,714,000 -1,781,000 1,090,000 5,240,000 3,456,000 -1,208,000 1,212,000 8,582,000 5,974,000 8,170,000 6,541,000 5,914,000 10,829,000 11,299,000 4,538,000 5,625,000 2,090,000 3,555,000 3,133,000
稅後淨利
411,000 4,473,000 48,000 3,123,000 -3,361,000 -2,376,000 2,338,000 5,556,000 5,003,000 8,622,000 9,912,000 7,870,000 3,392,000 8,159,000 5,589,000 4,886,000 1,314,000 2,161,000 3,464,000 3,401,000
折舊費用
1,791,000 1,755,000 1,731,000 1,736,000 1,670,000 1,560,000 1,573,000 1,487,000 1,519,000 1,183,000 1,175,000 1,187,000 1,335,000 1,399,000 1,347,000 1,226,000 1,204,000 1,366,000 1,303,000 1,218,000
調整項目
- -394,000 -25,000 -432,000 -1,518,000 5,473,000 -1,204,000 -325,000 -1,565,000 273,000 -148,000 -1,784,000 -733,000 -5,441,000 -1,332,000 -256,000 -877,000 1,421,000 462,000 87,000
應收帳款增減
- - - - 347,000 - - - 261,000 - - - -3,811,000 - - - -1,249,000 - - 0
存貨增減
- - - - -1,169,000 - - - 592,000 - - - -1,125,000 - - - -736,000 - - 0
其他營業活動資產增減
- 879,000 -3,535,000 -3,336,000 8,977,000 -1,199,000 -3,916,000 -5,507,000 3,030,000 -4,109,000 -2,766,000 -730,000 -13,090,000 6,714,000 5,679,000 -1,327,000 1,472,000 -1,024,000 -714,000 -1,581,000
負債增減
- - - - 295,000 - - - -258,000 - - - 19,963,000 - - - 3,094,000 - - 0
投資現金流
-1,623,000 -2,057,000 4,600,000 1,732,000 -10,996,000 888,000 -25,485,000 3,315,000 -4,410,000 -627,000 -11,313,000 567,000 -2,586,000 -10,076,000 -8,137,000 -1,747,000 8,330,000 481,000 -13,011,000 -71,000
資本支出增減
- -651,000 -637,000 -704,000 -1,044,000 -810,000 -914,000 -1,139,000 -1,001,000 -841,000 -751,000 -643,000 -1,002,000 -627,000 -540,000 -554,000 -839,000 -561,000 -493,000 -463,000
投資增減
-4,267,000 -1,412,000 5,256,000 2,435,000 33,438,000 1,350,000 -24,022,000 4,473,000 13,354,000 -3,635,000 -10,485,000 7,448,000 -1,645,000 -9,154,000 -7,362,000 -1,356,000 -1,795,000 -10,574,000 -12,547,000 420,000
其他投資活動現金流量
- 5,000 -18,000 - -43,391,000 350,000 -550,000 -18,000 -16,764,000 3,851,000 -78,000 -6,238,000 61,000 -295,000 -235,000 163,000 10,965,000 11,617,000 29,000 -28,000
融資現金流
-5,114,000 -4,636,000 -2,459,000 -4,931,000 5,442,000 -3,779,000 27,174,000 -2,771,000 -5,015,000 -5,761,000 2,520,000 -6,578,000 -3,351,000 -1,101,000 -2,557,000 -2,807,000 -13,787,000 -2,821,000 9,159,000 -2,200,000
賣出及買回股票增減
- - - - - - - - - - - -2,000,000 - - - - - - 158,000 124,000
借款增減
-2,720,000 -2,250,000 -16,000 -2,173,000 7,775,000 -1,428,000 29,630,000 -32,000 -2,777,000 -3,521,000 4,611,000 -1,829,000 -1,363,000 759,000 -474,000 -25,000 -11,993,000 10,835,000 11,320,000 18,000
其他籌資活動現金流量
-14,000 -6,000 -63,000 -386,000 -18,000 -37,000 -140,000 -436,000 7,000 5,000 154,000 -501,000 201,000 324,000 101,000 -610,000 -107,000 -11,749,000 -208,000 -237,000
自由現金流
6,721,000 6,063,000 -2,418,000 386,000 4,196,000 2,646,000 -2,122,000 73,000 7,581,000 5,133,000 7,419,000 5,898,000 4,912,000 10,202,000 10,759,000 3,984,000 4,786,000 1,529,000 3,062,000 2,670,000
淨現金流
-16,000 29,000 343,000 -2,137,000 -316,000 535,000 475,000 1,754,000 -869,000 -487,000 -688,000 529,000 -50,000 -384,000 608,000 -15,000 198,000 -218,000 -351,000 846,000
發文者頭像
發文者徽章

熱血鬥士

03月12日 07:53
Lv.24 
 
輝瑞乳癌新藥試驗結果好壞參半 合作夥伴Arvinas股價崩逾40% | Anue鉅亨 - 美股雷達
 

        輝瑞乳癌新藥試驗結果好壞參半 合作夥伴Arvinas股價崩逾40% | Anue鉅亨 - 美股雷達
      
 

        美國製藥巨擘輝瑞 (Pfizer)(PFE-US) 最新一代乳癌治療藥物「Vepdegestrant」在一項最終階段臨床試驗中顯示出憂喜參半的結果，這對於輝瑞曾經宣稱這款藥物有潛力成為重磅藥物的預期來說，可能是一個打擊。
      
 

        news.cnyes.com
      
 
 
  
 
 
 
   
 
 
  
 
 
 
      
     
     
       
       
       
       
       
       
       
       
       
     
    
          股市爆料同學會
        
     
          官方訊息
        
     
     
     
    下載APP享有即時報價，不用手動刷新！
     
     
    
      使用股市爆料同學會APP｜一起跟百萬網友討論！
    
     
      立即下載